PRKAA1 and type 2 diabetes mellitus: For example, enhancement of AMPK activity was shown to cause suppression of palmitate-induced inflammasomes activation [28], whereas deficiency of AMPK by a pharmacological inhibitor or siRNA enhanced IL-1β and IL-18 production in monocyte-derived macrophages from patients with type 2 diabetes [49].